Parkinson's disease gene therapy (Oxford BioMedica)

N/A

Report date: 2023/10/26 17:04:44

Base Information

Drug NameParkinson's disease gene therapy (Oxford BioMedica)
Drug Alias NameAADC and CH1帕金森病基因治疗 - 牛津生物医药Tricistronic lentiviral vector encoding for THProSavin (OXB-101)AXO-Lenti-PD +[8] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionGene transference
TargetsNot applicable
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOxford Biomedica
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOxford BiomedicaSio Gene Therapies Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A